AJ Lanigan: Yes. In Truth, pharma firms are making big revenue with therapies like Keytruda and Opdivo that deal with PD-1 and PD-L1. Right here’s the super interesting section: think about checkpoints as website traffic alerts. You don’t want an immune technique that’s operating wild like a freight educate above waiting for link from Social Bookmarking (4)